Every Form 4 that Palisade Bio Inc (PALI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PALI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALI filings page.
PALISADE BIO, INC. (PALI) reported that its CEO and CFO, John David Finley, made an internal reallocation of holdings through bona fide gifts of common stock on August 19, 2026. He transferred 88,400 shares of common stock from his direct ownership to FCW Investments, LLC, an entity he manages.
After these related gift transactions, Finley directly holds 129,288 shares of Palisade Bio common stock and indirectly holds 88,451 shares through FCW Investments, LLC, over which he has sole investment and voting power. The Rule 10b5-1 trading plan checkbox was not marked for these transactions.
PALISADE BIO, INC. director Robert Baltera Jr. reported two open-market purchases of Common Stock. He bought 20,000 shares on July 8, 2026 at a weighted average price of $1.9899 per share, and 25,000 shares on July 9, 2026 at a weighted average price of $1.9560 per share. Following these transactions, he directly holds 461,904 shares. Each daily price is a weighted average of multiple trades within the stated intraday price ranges.
Palisade Bio director Robert Baltera Jr. reported open-market purchases of a total of 50,000 shares of common stock. He bought 20,000 shares on July 6, 2026 at a weighted average price of $2.052 per share and 30,000 shares on July 7, 2026 at a weighted average price of $2.0348 per share. The filing notes the trades were executed in multiple transactions within price ranges of $2.04–$2.068 and $2.00–$2.07. Following these purchases, Baltera directly owns 416,904 shares of Palisade Bio common stock.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones reported routine equity compensation activity involving restricted stock units (RSUs) and related tax sales. On July 6, he exercised 131,167 RSUs into an equal number of common shares at a stated price of $0.00 per share, reflecting settlement of vested awards granted on February 9, 2026. As part of this vesting, 51,880 common shares were sold at a weighted average price of $2.0535 per share solely to cover tax withholding obligations, with individual sale prices ranging from $2.045 to $2.06. Following these transactions, Jones directly holds 94,009 shares of common stock and 655,833 RSUs, which continue to vest with 1/6 of the RSUs scheduled to vest on July 6, 2026 and the remainder vesting quarterly over the next 10 quarters, subject to his continued service. His holdings also include 1,459 shares acquired under the company’s Employee Stock Purchase Plan on May 20, 2026.
PALISADE BIO, INC. CEO and CFO John David Finley reported routine equity compensation activity, including RSU settlement, warrant exercise, and a related share sale to cover taxes. On July 6–7, 2026, he acquired 335,167 common shares through vested Restricted Stock Units and 133 shares via exercise of a Series 2 warrant at $0.70 per share. He then sold 146,798 common shares at a weighted average price of $2.0664 per share solely to satisfy tax withholding obligations tied to the RSU vesting. After these transactions, he holds 217,688 common shares directly and 51 shares indirectly through FCW Investments, LLC, over which he has sole voting and investment power.
Palisade Bio director Robert Baltera Jr. bought a total of 30,000 shares of Palisade Bio common stock in open-market transactions, paying $1.98 per share. The purchases occurred over two days and increased his direct holdings to 366,904 shares.
The filing notes that the reported price is a weighted average, with individual trades executed between $1.97 and $1.99 per share. These transactions represent additional personal investment in the company by a board member, rather than option exercises or compensation-related grants.
Baltera Robert Jr. reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio director Robert Baltera Jr. received a grant of 336,904 Restricted Stock Units (RSUs) of common stock. Each RSU represents a right to one share and was awarded at $0.00 per share. The RSUs vest in three equal annual installments starting on June 10, 2026, contingent on his continued service, and his reported direct holdings after this grant are 336,904 shares.
Palisade Bio director Binxian Wei reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 10, 2026, Wei received a grant of 592,300 RSUs of Palisade Bio common stock at no cash cost.
The filing also shows 20,200 RSUs converting into the same number of common shares as they vested on June 10, 2026. One line reports 613,355 common shares held directly after the RSU vesting, and another reports 593,155 shares after the new RSU grant. The RSU awards are subject to service-based vesting over three annual installments tied to future stockholder meetings or specified anniversaries, so Wei must remain in service for full delivery of shares.
Palisade Bio director Donald Allen Williams increased his equity stake through stock-based compensation rather than market trades. He received a grant of 1,498,900 restricted stock units (RSUs) that vest in three equal annual installments starting on the earlier of the 2027 annual stockholders meeting or the anniversary of June 10, 2026, subject to continued service. On June 10, 2026, 60,666 previously granted RSUs vested and were converted into Common Stock at no cash exercise price, contributing to direct ownership of 1,509,628 common shares and 121,334 remaining RSUs. He also has 3,000 additional shares held indirectly through his defined benefit plan.
PALISADE BIO director Emil Chuang reported equity-based compensation and an RSU vesting. On June 10, 2026, he exercised restricted stock units (RSUs) into 20,200 shares of common stock and received an additional grant covering 592,300 shares, both at a stated price of $0.00 per share.
The RSU grants are subject to service-based vesting. One grant vests in three equal annual installments starting on the earlier of the 2027 annual meeting of stockholders or the anniversary of June 10, 2026, contingent on continued service. Another RSU grant vested in full on June 10, 2026.
Zwick Jordan Michael reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio director Jordan Michael Zwick reported receiving a grant of 336,904 shares of Common Stock in the form of Restricted Stock Units as compensation. These RSUs carry a zero dollar grant price and will vest in three equal annual installments starting on June 10, 2026, contingent on his continued service with the company. After this award, the filing shows Zwick holding 336,904 shares directly.
Jones Mitchell Lawrence reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 17,989 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 13,263 shares.
Finley John David reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 30,562 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 27,353 shares.
Jones Mitchell Lawrence reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones was granted 787,000 restricted stock units on February 9, 2026. Each RSU represents a contingent right to receive one share of Palisade Bio common stock, though the units may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs are scheduled to vest as to 1/6 of the award on July 6, 2026, with the remaining portions vesting quarterly over the following 10 quarters. Vesting depends on Jones maintaining continuous service with the company through each vesting date.
Palisade Bio, Inc. reported that CEO and CFO Finley John David acquired a grant of 2,011,000 Restricted Stock Units (RSUs) on February 9, 2026. Each RSU represents a right to receive one share of common stock, though the RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs will vest as to one-sixth of the units on July 6, 2026 and then vest quarterly over the following 10 quarters, conditioned on Finley’s continuous service with the company through each vesting date. Following this grant, he directly holds 2,011,000 derivative securities in the form of RSUs.
Palisade Bio director Donald Allen Williams reported a purchase of company stock. On January 16, 2026, he bought 5,000 shares of common stock at a price of $1.6712 per share, increasing his direct holdings to 10,728 shares.
In addition to his direct ownership, the filing shows an indirect holding of 3,000 common shares through the reporting person's defined benefit plan. This Form 4 reflects insider activity by a company director, providing transparency about changes in his ownership stake.
Palisade Bio, Inc. director Donald Allen Williams reported buying 5,000 shares of common stock on January 9, 2026 at a price of $1.88 per share. After this open-market purchase, he directly owns 5,728 common shares and has an additional 3,000 shares reported as indirectly owned through the reporting person's defined benefit plan.
Palisade Bio, Inc. (PALI) filed an amended Form 4 reporting a corrected equity award to a director. On 10/06/2025, the reporting person acquired 182,000 Restricted Stock Units (RSUs) at $0, with 182,000 derivative securities beneficially owned directly after the transaction.
The amendment corrects a previously reported grant of 1,538,700 RSUs; the issuer has rescinded 1,356,700 of that prior amount. Each RSU represents a right to receive one share of common stock; until sufficient shares are reserved under the 2021 Equity Incentive Plan, RSUs may be settled in cash upon vesting.
The RSUs vest in three equal annual installments, with the first installment vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.
Palisade Bio (PALI) filed a Form 4/A amending a director equity award. The company corrected a previously reported grant, stating that the award is 60,600 RSUs after the issuer rescinded 450,100 RSUs from an initially reported 510,700 RSUs on 10/06/2025.
Each RSU represents a right to one common share, though settlement may be in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, with the first vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, contingent on continued service.
Palisade Bio (PALI) filed a Form 4/A amending a prior equity grant for a director. The filing reports 60,600 restricted stock units (RSUs) granted on October 6, 2025, shown at a derivative security price of $0 with 60,600 derivative securities beneficially owned on a direct basis.
The amendment corrects a previously reported grant of 510,700 RSUs; the issuer has rescinded 450,100 of those RSUs. Each RSU represents a contingent right to one share, though RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, with the first vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, subject to continuous service.
Donald Allen, a director of Palisade Bio, Inc. (PALI), was granted 1,538,700 Restricted Stock Units (RSUs) with a transaction date of 10/06/2025. Each RSU converts into one share of common stock unless the company lacks reserved shares, in which case the RSUs may be settled in cash. The RSUs vest for service in three equal annual installments, to be satisfied on the earlier of the next annual meeting of stockholders or the anniversary of 10/06/2025, subject to continued service. Following the grant, the reporting person beneficially owns 1,538,700 shares (direct).
Palisade Bio director Wei Binxian received 510,700 restricted stock units (RSUs) on 10/06/2025. Each RSU converts to one share of common stock when settled, but may be cash-settled if sufficient shares are not reserved under the 2021 Equity Incentive Plan. The RSUs vest in three equal annual installments, each satisfied on the earlier of the next annual meeting of stockholders or the anniversary of 10/06/2025, subject to continuous service.
The reported holding after the grant is 510,700 shares beneficially owned, held directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 10/08/2025.
Palisade Bio issued a grant of 7,665,800 restricted stock units (RSUs) to its Chief Medical Officer, representing a contingent right to receive one share per RSU or, if shares are not available, a cash settlement. The RSUs vest in three equal parts: 1/3 on 10/06/2026 with the remaining two thirds vesting quarterly over the following eight quarters, contingent on the officer's continuous service. The grant carries a $0 exercise/settlement price per share and is recorded as a direct beneficial holding of 7,665,800 common shares once settled. The filing reports the insider transaction dated 10/06/2025 and is signed by an attorney-in-fact on behalf of the reporting person.
Palisade Bio reported that John David Finley, a director and officer (CEO, CFO), was granted 9,179,400 restricted stock units (RSUs) on 10/06/2025. Each RSU converts to one share of common stock when settled, though RSUs may be paid in cash if there are not enough shares reserved under the 2021 Equity Incentive Plan. The RSUs vest 1/3 on 10/06/2026 and then quarterly over the next eight quarters, conditioned on continuous service. The reported grant has a $0 per-share exercise/settlement price and is held directly by the reporting person.
Director Emil Chuang received an award of 510,700 restricted stock units (RSUs) on 10/06/2025. Each RSU converts to one share of common stock when settled, although the company may pay cash instead if there are not enough shares reserved under the 2021 Equity Incentive Plan. The RSUs vest for service in three equal annual installments, payable on the earlier of the next annual meeting or the anniversary of 10/06/2025, subject to continuous service. Following the reported grant, the Reporting Person beneficially owns 510,700 shares on a direct basis. The Form 4 was signed by an attorney-in-fact on 10/08/2025.